Allergan Issues Recall of Taytulla Birth Control

Article

Allergan has issued a voluntary recall in the United States for a single lot of its norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules (Taytulla) physician sample packs.

Allergan has issued a voluntary recall in the United States for a single lot of its norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules (Taytulla) physician sample packs, due to the incorrect placement of placebo pills in the pack.

Caught through a physician report of the pregnancy prevention product, the lot in question has been identified by Allergan as Lot #5620706 (Expiry May 2019). The packs were of the 1 mg/20 mcg 6x28 quantity.

Specifically, the first 4 days of the capsules were packaged with 4 non-hormonal placebo capsules in place of their active counterparts. The product was distributed nationally to health care providers, according to Allergan.

Click to continue reading on MD Magazine.

Related Videos
Aimee Keegan, PharmD, BCOP, a clinical pharmacist
Aimee Keegan, PharmD, BCOP, a clinical pharmacist
Video 2 - "Achieving Post-Discharge Success: Goals in Hepatic Encephalopathy Care"
Video 1 - "Identifying and Screening for Hepatic Encephalopathy Risk Factors"
© 2024 MJH Life Sciences

All rights reserved.